Search This Blog

Friday, December 18, 2020

Fibrogen falls in post-market ahead of FDA decision

 

  • Fibrogen (NASDAQ:FGEN) is down -9.5% in the post-market trading as the company awaits the FDA decision for its small molecule therapy Roxadustat, for the treatment of anemia of chronic kidney disease.
  • In February, the company announced the acceptance of its marketing application by the FDA with PDUFA date set for December 20. The submission is backed by a phase 3 trial involving more than 3,000 patients worldwide.
  • A collaboration with AstraZeneca (NASDAQ:AZN), the drug is already approved in China and Japan for CKD, and the European regulator accepted the company's marketing application in May.
  • https://seekingalpha.com/news/3645986-fibrogen-falls-in-post-market-ahead-of-fda-decision

FDA gives Moderna's COVID vaccine emergency use authorization

 

  • Moderna (NASDAQ:MRNA) gets emergency use authorization of mRNA-1273, its vaccine against COVID-19, from the U.S. Food and Drug Administration, making it the second vaccine to gain EUA in an effort to stem the pandemic.
  • Delivery of the vaccine to the U.S. government will begin immediately; ~20M doses will be delivered by the end of December.
  • The U.S. government has ordered a total of 200M doses of the Moderna vaccine to date and has an option to buy up to an additional 300M doses.
  • Moderna will continue to gather additional data and plans to file a Biologics License Application with the FDA requesting full licensure in 2021.
  • Earlier today, Moderna announced that the European Commission exercised its option to buy an additional 80M doses of the vaccine, bringing its total order commitment to 160M doses.
  • https://seekingalpha.com/news/3646013-u-s-fda-gives-modernas-covid-vaccine-emergency-use-authorization

Why aren't Lilly, Regeneron Covid antibodies getting to more patients?

 About a month after the FDA issued emergency authorizations for COVID-19 antibodies from Eli Lilly and Regeneron, most of them have gone unused, a federal official said Wednesday. As hospitals and healthcare officials scramble to get the treatments to more people who need them, the companies said they're also involved in efforts to make the drugs more available.

So far, the government has distributed 250,000 antibody doses to states and territories, federal data show, but only around 5% to 20% have been used, Operation Warp Speed head Moncef Slaoui told CNBC.

The drugs—which scored emergency nods last month—are authorized for patients with mild to moderate COVID-19 and who are at a high risk of developing severe disease because of their age or underlying health conditions. 

But the treatments are infused, and many patients who could benefit aren’t already in a healthcare setting—such as a hospital—where they can be identified and treated. Even if they were to get a prescription, they might not have easy access to an infusion center where doses can be administered. Complicating matters is the fact that infectious patients need to be isolated, as Reuters notes.

 

A Lilly spokeswoman said the government purchased 950,000 doses of bamlanivimab, its antibody therapy, to be delivered through the end of January. So far, the government has delivered nearly 200,000 doses of the drug to states and other authorities.

“The intravenous administration of therapeutics to patients with confirmed mild to moderate COVID-19 presents unique challenges to the healthcare system, which could contribute to the utilization rates shared by [Operation Warp Speed],” she said. “Lilly is partnering with stakeholders to address challenges and ensure patients who need bamlanivimab can get it.” 

Hospitals and health officials are scrambling to respond. In Utah, for instance, the Intermountain Healthcare system is testing “MAb Squads," which quickly get in touch with high-risk patients after a diagnosis and offer information about infusion centers, Reuters reports

Operation Warp Speed is testing a pilot with CVS for at-home infusions, Lilly’s spokeswoman said. New infusion sites are coming online, she added, and some existing sites are expanding their hours.  


For its part, Regeneron “has provided tens of thousands of doses for distribution,” a spokeswoman said. While the government is in charge of allocating the drug, Regeneron is “committed to ensuring equitable access to the antibody cocktail" and is also working on solutions, she added.

Regeneron expects to have doses for around 200,000 patients ready by the first week in January and enough for 300,000 patients by the end of January. The company is partnered with Roche to make at least 2 million doses in 2021. 

Meanwhile, even as the first COVID-19 vaccines reach Americans, former FDA commissioner Scott Gottlieb is calling on the federal government to assist with a scale-up of antibody supplies as an “insurance policy” against the coronavirus pandemic next year. If vaccines fall short of expectations, antibodies could provide a major boost in the fight against the virus, he wrote in a Wall Street Journal op-ed

https://www.fiercepharma.com/pharma/amid-challenging-covid-19-antibody-rollouts-hospitals-double-down-efforts-to-get-drugs-to

Covid-19 Vaccine Advice Leaves Some People With Allergies in Limbo

 Severe allergy sufferers say they are confused about whether they should get the Covid-19 vaccine made by Pfizer Inc. and BioNTech SE, and public-health authorities on both sides of the Atlantic are offering conflicting advice.

The U.K.'s medical regulator warned people with severe allergies to food, vaccines or medicine against getting the Pfizer-BioNTech vaccine after two severe allergic reactions among vaccine recipients in that country.

Two health-care workers in Alaska also experienced allergic reactions after receiving the vaccine, one which required hospitalization. In contrast to the U.K. regulator, the U.S. Food and Drug Administration and Health Canada have advised only against administering the shot to people with a known history of severe allergic reaction to any component of the vaccine itself.

Some patients in the U.S. and U.K. said they were puzzled and unsure about what advice to follow.

"I'm definitely concerned about it," said Abigail Espinoza, a 43-year-old mother of three and architectural design student in Astoria, Ore., who said the U.K. incidents worried her. She has severe allergies to pistachios and penicillin, which can lead to issues with her breathing. To treat possible allergic reactions, she carries an epinephrine auto-injector.

Ms. Espinoza, who isn't among the first group of people being vaccinated, said she isn't planning to receive the Pfizer-BioNTech vaccine until there are more data and research available on the vaccine and people with allergies. She also wants to consult an allergist before getting a shot.

Doctors say they are fielding a flood of questions from patients with various types of allergies, who say they aren't sure what to do once they become eligible.

Doctors fear that the cases of severe reaction and the contradictory advice around allergies will discourage patients from getting the vaccinated, as the Pfizer-BioNTech vaccine rolls out, with Moderna Inc.'s Covid-19 vaccine likely to come soon.

Niraj Patel, an allergist and chair of the American College of Allergy, Asthma and Immunology Covid-19 Task Force, said he has been getting a lot of questions about whether people with allergies are at higher risk of having a serious reaction to the vaccine. "They want to know whether it's safe to receive," he said.

Dr. Patel and other allergy experts in the U.S. have been telling concerned patients that only people with a history of severe allergic reactions to a specific component of the vaccine -- particularly a compound called polyethylene glycol -- shouldn't receive the vaccine. Otherwise, having a severe allergy to foods or oral medications doesn't increase your chance of an allergic reaction to the vaccine, he said.

Allergists find that some people can have allergies that are related to each other. For instance, people who are allergic to one type of nut may also be allergic to other types of nuts because they contain similar chemical structures, something known as cross-reactivity, Dr. Patel said.

"There doesn't seem to be any cross-reactivity between agents that are in the Covid vaccine and other common proteins that cause anaphylaxis, such as food or drugs," he said. Anaphylaxis is the most severe form of an allergic reaction, which can result in airway closure and death.

Before the U.K.'s rollout of the Pfizer vaccine on Dec. 8, that country's advice was in line with its guidance for all vaccines and mirrored Pfizer and BioNTech's recommendations for their shot: Those with allergies to the vaccine or its components shouldn't take it.

Chris Whitty, chief medical officer for England, said the U.K. altered its advice based on reactions in the real world that hadn't happened in the clinical trials. That has led to an improvement over time in the number of cases of anaphylaxis after injections, Mr. Whitty said Wednesday.

Sometimes the ingredient that triggered the reaction -- the allergen -- isn't known, said the U.K.'s Medicines and Healthcare Products Regulatory Agency. "That's why, as a precautionary measure, our current advice is that any person with a history of immediate-onset anaphylaxis to a vaccine, medicine or food should not receive the Pfizer-BioNTech vaccine," an MHRA spokeswoman said. "Further investigation into these cases is ongoing," she added.

Professor Saad Shakir, director of the drug safety research unit in the U.K., said the decision to broaden the restrictions on vaccine recipients was "the correct risk-minimization action."

"It is reassuring that the decision was made and communicated so promptly," he said.

Anaphylaxis after vaccines generally happens only around once per every million doses, according to the ACAAI. People who have had severe allergic reactions, such as anaphylaxis, to any component in the Pfizer-BioNTech vaccine shouldn't receive the vaccine, according to the FDA and the U.S. Centers for Disease Control and Prevention. The vaccine components can be found on the FDA's website.

People with severe allergies to any other vaccine or injectable may receive the vaccine, but should speak with their medical providers beforehand about weighing the risks of an allergic reaction with the benefits of receiving the vaccine, the agency advises. And there is no reason why people who have a history of mild or severe allergic reactions to food, pets, oral medications or environmental allergens such as pollen shouldn't receive the vaccine, the CDC says.

The CDC also says all recipients of the vaccine should be observed for 15 minutes after vaccination to monitor for possible adverse reactions. People with a history of anaphylaxis should be observed for 30 minutes after vaccination, it says.

Pfizer and BioNTech have said that people with severe allergic reactions to the vaccine or its component parts shouldn't receive the shot. The vaccine's clinical trials didn't include people with that profile, according to the companies.

Anaphylaxis wasn't observed during clinical trials of the Pfizer-BioNTech vaccine, though 0.63% of a subset of vaccinated participants in the later-stage trials had so-called hypersensitivity-related adverse events, which could have been allergic reactions. In the placebo group, 0.51% had these reactions.

Moderna said that there had been one anaphylactic reaction in a vaccine recipient in its study, but it occurred two months after the second dose in a person with a history of asthma and allergy to shellfish. Allergists say it is unlikely for anaphylactic reactions to happen in such a delayed manner; most reactions would occur within minutes. The company said it plans to continue monitoring such events.

Some U.S. vaccine and allergy experts said they disagreed with the U.K.'s decision to bar all people with severe allergies to food, medicine or vaccines from getting vaccinated. They said such a policy is too broad, given that there were only two cases of severe allergic reactions in the U.K. out of 138,000 doses given in the first week.

"You're talking about eliminating tens of millions of people" from the vaccination program if you bar people with severe allergies to food or medicines from getting the injection, said Paul Offit, a vaccine expert at the Children's Hospital of Philadelphia who is on the FDA's Covid-19 vaccine advisory panel. The FDA said it was investigating the two allergic reactions in Alaska.

People with allergies need to understand that they are generally at the same risk of having an allergic reaction to the vaccine as anyone else, he said. "We need to offer people some solace that this is not going to be a problem for them," Dr. Offit said.

https://www.marketscreener.com/quote/stock/PFIZER-INC-23365019/news/Covid-19-Vaccine-Advice-Leaves-Some-People-With-Allergies-in-Limbo-32047665/

Airports advised to step up security efforts for COVID-19 vaccine cargo

 Airports around the world are being advised to step up security efforts to protect COVID-19 vaccine shipments amid police warnings of potential targeting from criminal networks.

The recommendation from a global airports body comes as pharmaceutical companies and airlines are carrying out the largest logistical operation of its kind to distribute vaccines designed to combat the global pandemic.

As part of a broader advisory bulletin on vaccine distribution recently sent to members, Airports Council International recommended affected airports liaise with local authorities and conduct risk assessments on shipments given potential threats.

The bulletin was posted Friday on the group's website, a spokesman said.

"The sensitive nature of the vaccines, the high level of demand there will be for obtaining them and the initial short supply has the potential to generate some attention by persons or groups with malicious intent," it said.

"Consideration should be given to increased protection of these goods and/or the facilities that will house them. In many cases, this requires coordination with local security authorities."

The Interpol global police co-ordination agency recently warned that organized criminal networks could be targeting COVID-19 vaccines, possibly through the infiltration or disruption of supply chains. The bulletin also advised airports to consider safety precautions given the use of large volumes of dry ice required to meet the vaccines' ultra-cold requirements. The transportation of dry ice is regulated as it is considered to be a “dangerous good."

Discussions are underway at the United Nations aviation agency to "increase the volume of dry ice that may be transported in a single aircraft, provided strict protocols are followed," it noted.

A vaccine developed by Pfizer Inc and German partner BioNTech SE has begun to be administered to people in the United States and Britain and a second vaccine, from Moderna Inc, is expected to win regulatory approval from the U.S. Food and Drug Administration within days.

https://www.marketscreener.com/quote/stock/ASTRAZENECA-PLC-4000930/news/AstraZeneca-Airports-advised-to-step-up-security-efforts-for-COVID-19-vaccine-cargo-32048428/

Moderna Analysts on Adcom, Vaccine Distribution And Commercialization

 Moderna Inc's 

MRNA 1.07% coronavirus vaccine candidate, mRNA-1273, got FDA panel backing, in line with expectations, and is likely to be accorded emergency use authorization any time now.

An Unsurprising Decision: The 20-0 vote, with one abstention, in favor of issuing an EUA for mRNA-1273 in patients 18 years and older, is not surprising, given the high overall vaccine efficacy of 94.5% and protection across all subgroups, SVB Leerink analyst Mani Foroohar said in a note.

Needham analyst Alan Carr noted the member who abstained expressed reservations about the vaccine being administered to the broader population before additional data is available. Instead, he preferred administration to high-risk individuals for the time being.

No substantial concerns were raised regarding the safety profile.

Discussion Points: The vaccine committee discussed at length on unblinding and crossover of placebo recipients in the Phase 3 study, safety and vaccine durability, Foroohar said.

Carr noted FDA is in favor of maintaining the blind in order to generate additional placebo-controlled safety data as a means of providing valuable long-term insight into the safety profile of the vaccine.

With both Pfizer Inc. PFE 1.15% and Moderna arguing for giving the subject's option to be unblinded and receive vaccine, the committee gradually began to lean towards providing subjects an option to unblind, the analyst said.

EUA Imminent, Focus Shifts to Distribution, Commercial Aspects: Carr said he expects the FDA to grant a EUA very soon.

CDC's ACIP meetings are scheduled for Saturday and Sunday to discuss mRNA-1273 as well as allocation of COVID-19 vaccines in Phases 1b and 1c, the analyst said.

Moderna's mRNA-1273 is shipped at -20 degrees Celsius as a single carton containing 100 doses, and each vial contains 10 doses, with no dilution required, he added.

The vaccine remains stable at 4 degrees Celsius for 30 days and at room temperature for 12 hours, Carr said.

Needham estimates mRNA-1273 is likely to fetch Moderna revenues of $7.28 billion in 2021, assuming shipment of 500 million doses globally.

"We acknowledge the enormous accomplishment in the development of a vaccine for COVID-19 in a very short period of time, but believe the stock is fairly valued and maintain HOLD," the firm said.

https://www.benzinga.com/analyst-ratings/analyst-color/20/12/18853097/moderna-analysts-discuss-adcom-verdict-distribution-and-commercialization-of-corona

Amwell drops as Stifel calls for a better entry point

 

  • American Well Corporation (NYSE:AMWL) drops -2.3% as Stifel initiates coverage with a ‘Hold’ recommendation, suggesting ‘there may be a more opportunistic time to initiate or add to current positions.’
  • Noting Amwell as a significant beneficiary of the pandemic, the analyst David Grossman writes the company ‘has catalyzed secular growth tailwinds independent of the economic cycle,’ which he identifies as a combination, supporting the current valuation multiple of ~23x in terms of 2021 revenue.
  • Despite being comfortable with ‘company specific fundamental outlook near-intermediate term,’ the analyst doubts the impact of market sentiment on the multiple setting a price target of $29 for the stock.
  • https://seekingalpha.com/news/3645834-amwell-drops-stifel-calls-for-better-entry-point